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Summary In cancer treatment, extravasation is de-
fined as an inadvertent instillation or leakage of cy-
totoxic drugs into the perivascular space during infu-
sion. As a dreaded complication of chemotherapy, ex-
travasation has gained increasing attention in recent
years. Classified according to their subcutaneous tox-
icity, three types of cytotoxins have been established:
vesicants, irritants and nonvesicant drugs. Vesicant
cytotoxic drugs may induce tissue damage, ulceration
and tissue necrosis. Although we have established
measures to manage extravasation emergencies, pre-
vention is of paramount importance. This may be
achieved within hospitals through regular training and
education, which is best provided by a specialised
and experienced task force including all disciplines in-
volved in cancer therapy. Moreover, clinical and trans-
lational studies contribute to a better management of
chemotherapy-induced extravasation as shown by our
group in recent years. We were able to demonstrate
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that the evaluation of blood flow by indocyanine green
angiography in the extravasation area predicts the ex-
tent of damage and the need of future surgical in-
tervention. When a Port-a-Cath® extravasation is de-
tected early, a subcutaneous wash-out procedure was
found to be beneficial, corroborated by the analytical
evaluation of the removed cytotoxic compound epiru-
bicin. In another study, the tissue distribution of plat-
inum was quantified at the anatomic level in cryosec-
tions of various tissues. This novel knowledge com-
plements and supports our current efforts to handle
extravasations better. On the other hand, a number
of new drugs (chemotherapy, monoclonal antibodies,
checkpoint inhibitors etc.) with many open issues to
reliably classify their tissue toxicity still require our
attention.
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Background
Extravasation of cytotoxins is referred to as the unin-
tended instillation or leakage of drugs into the perivas-
cular space or into the subcutaneous tissue during
infusion. With large variations, this complication has
been reported in 0.1–6.5% of cytotoxic infusions [1].
The local damage, now predictable with angiography
[2], depends on the toxicity of the extravasated com-
pound and the amount of the drug in the affected
lesion [3]. We distinguish three different classes of
compounds: (1) nonvesicant substances with no
signs of local irritation, (2) irritant substances, which
may cause local pain, swelling and irritations, but
no necrosis and (3) vesicant substances, which may
eventually cause ulcerations and necroses. Extravasa-
tions of vesicants may require surgical interventions
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such as débridement with subsequent skin and tissue
transplantation with long-term consequences for the
patient [1].
Our approach
At the Comprehensive Cancer Center of the Medi-
cal University of Vienna, we established a task force
to manage extravasation complications and applied
a standardised protocol to treat patients after extrava-
sation. The outcome of this interventions, described
in Pluschnig et al., shows that a trained and instructed
task force can often prevent surgical interventions
even after extravasation of vesicants [4]. The required
knowledge includes e. g. the type of damage, patient
predisposition and individual risk factors, differen-
tial diagnosis of suspected extravasations to exclude
thrombophlebitis or hypersensitive reactions, close
monitoring and local management after extravasa-
tion with specific antidotes and supportive measures.
In a large series of patients examined in detail,
we evaluated the vesicant potential, type and volume
of infusion solutions, duration of exposure, local-
isation of extravasation, emergence of local com-
plications including blister formation, ulceration or
necrosis. We applied appropriate measures includ-
ing analgesic treatment, antidote administration and
other supportive measures and documented the time
course until complete remission of symptoms. With
a close follow-up programme, the observed com-
plications were mostly erythema, oedema and pain
(acute symptoms), blistering and ulceration (delayed
complications) and rarely sequelae with impairment
of functions or aesthetics (late sequelae). In addi-
tion to substance-specific interventions, a series of
nonspecific measures to accelerate the extravasation
recovery was started (for a detailed description see
supplementary material in reference [4]).
In 92% of 169 patients, conservative management
was successful with surgical interventions necessary
in only 14 patients. Extravasations of anthracyclines,
platinum compounds, vinca alkaloids and taxanes
were often associated with erythema, oedema and
pain. Most interestingly, the period until full reso-
lution of symptoms significantly differed among the
administered cytotoxins between a median of 14 days
(platinum compounds) and 55 days (anthracyclines).
Even after surgical intervention, lesions healed
within 14 days (median). This reduced the delay in
the administration of chemotherapy to a minimum
and none of the patients missed the scheduled treat-
ment. Despite these promising results in the prompt
management of extravasations, preventive measures
should be given absolute priority: they are the only
really safe strategy. Prevention, on the other hand,
needs educational and training programmes to be es-
tablished and to maintain the level of skills required
in the clinical routine setting.
Table 1 Vesicant cytotoxins
Amsacrine Mitomycin C







General management of extravasation
The general management of cytotoxic extravasations
has been reviewed in several excellent manuscripts
and has changed little over time [1, 5–7]. These gen-
eral measures after extravasation of nonvesicants ba-
sically include the following:
1. Stop injection/infusion immediately,
2. Get extravasation kit,
3. Put on (sterile) gloves,
4. Replace infusion lead or syringe with 5ml dispos-
able syringe and aspirate slowly as much as pos-
sible of the extravasated drug; Cave! do not exert
pressure on extravasation area,
5. Remove i. v. access while aspirating,
6. Elevate limb and immobilise,
7. Complete extravasation documentation sheet (men-
tion extent of extravasation),
8. Inform and instruct the patient and relatives,
9. Control the patient regularly until full resolution of
symptoms.
With regard to irritants or vesicants, substance specific
measures are additionally started, if available. With
vesicants (Table 1), please consult a (plastic) surgeon
within 24 h to decide about early surgical intervention
(flash-out technique [8] or explantation of central ve-
nous devices [9]).
Substance-specific management
The treatment of anthracycline extravasation with
a combination of DMSO (dimethyl sulfoxide) and
topical cooling is an established intervention, based
on a successful prospective clinical trial [10]. After
extravasation, topical DMSO should be applied im-
mediately covering the affected skin area. DMSO
penetrates tissue rapidly, is a local anaesthetic, is
vasodilatory and anti-inflammatory.
In July 2007, dexrazoxane was registered as antidote
after anthracycline extravasation based on the results
of two prospective multicentre trials [11]. Although
an active compound, there is no head-to-head com-
parison between dexrazoxane and DMSO/cooling.
Besides a number of adverse events associated with
dexrazoxane, medication costs of around 10,000
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(versus 6 for DMSO) are another issue in times of
pharmacoeconomic-based distribution of resources.
After extravasation of vinca alkaloids, the enzyme
hyaluronidase accelerates local connective tissue
breakdown and absorption of the extravasated al-
kaloid. A dose of 1500 IU hyaluronidase is injected
subcutaneously in combination with dry topical heat
[12].
In case of extravasation, occlusive dressings or
moist heat or cold should never be applied, as this
increases the risk of skin maceration or necrosis.
This short summary of substance specific measures
shows that we have no specific interventions for a va-
riety of irritant and vesicant drugs. There is more
than room for improvement in this area and every
additional and effective intervention would be highly
acclaimed.
Trabectedin should be administered through a cen-
tral venous catheter to minimise the risk of extravasa-
tion [13]. Approved as monotherapy for advanced soft
tissue sarcomas after anthracycline failure in 2007, lo-
cal pain, blistering and necrosis has been sporadically
described in case reports after extravasation [14]. In
our study, two patients experienced a trabectedin ex-
travasation with local redness, pain and a local de-
marcation of the affected area. In one patient, these
symptoms fully resolved, whereas the other patient
developed soft tissue necrosis resulting in the need
for surgical intervention. Trabectedin has therefore to
be classified as a vesicant, where no specific antidote
is available.
Still open for discussion
Monoclonal antibody-based treatment of cancer has
been established as one of the most successful thera-
peutic strategies in cancer therapy in the last 20 years.
Despite limited information with regard to extravasa-
tion events, we classified antibodies as irritants prob-
ably due to local allergic reactions rather than direct
cellular toxicity.
In immune therapy of cancer, checkpoints in-
hibitors restore immune system function and have
proven their usefulness in a variety of cancers. When
treated with the checkpoint inhibitors ipilimumab
or nivolumab, thrombophlebitis may indicate some
irritant potential. Analogue observations seem to
apply to the proteasome inhibitors bortezomib or
carfilzomib (symptoms: local swelling and redness).
Clinical research
In three clinical investigations, different aspects of
extravasation have been investigated by our group.
These questions were the following:
1. Persistence of extravasated drug in the lesion,
2. Prediction of extravasation damage in severe cases,
3. Port-a-Cath® management after extravasation of
vesicants.
In the first extravasation study, we examined the
platinum concentrations in different tissues at an
anatomical resolution by laser ablation inductively
coupled mass spectrometry (LA-ICP-MS). For cis-
platin, a concentration-dependent risk seems to exist.
Analysing different tissues (connective tissue, muscle,
nerves and adipose tissue), platinum concentrations
were still high several weeks after the extravasation.
Remarkably, connective tissue seemed to enrich plat-
inum by a factor of 50 when compared with muscle.
This bioimaging technique opens up new possibilities
for studying the dose-response correlation of selected
compounds at high resolution and discriminates be-
tween different tissue types [15].
As a reliable method for early assessment of tis-
sue damage and outcome prediction is still missing,
we focused on the evaluation of blood flow by indo-
cyanine green (ICG) angiography in the extravasation
area and its predictive value for the need of surgical
intervention in the second study [2]. In all, 29 patients
were evaluated by this technique after extravasation of
vesicant or highly irritant cytotoxic drugs after periph-
eral i. v. infusion. In fact, the perfusion index in the
affected lesion differed significantly between patients
with reversible tissue damage and those who needed
Fig. 1 Determination of perfusion at the central area of the ex-
travasation lesion by indocyanine green angiography: conser-
vative management versus surgical intervention. Using indo-
cyaninegreenangiographyafterextravasation, thebloodflowof
patients with different clinical outcome was prospectively com-
pared. Box plots represent cutaneous blood flow as assessed
bytheperfusionindex inpatientswithconservativeclinicalman-
agement (n= 22) versus patients requiring surgical intervention
(n=7); a perfusion index of 100% isconsidered the normal refer-
ence. Figure reproduced from [2]
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Fig. 2 Indocyanine green
angiography ina patientwith
ulceration after extravasa-
tion of the vesicant vinorel-
bine. Ulceration on dorsum
of the hand with marked re-
gions of interest for imaging
(redcentral area of the ex-
travasation lesion,blue sur-
rounding margin, but within
the affected area of the le-
sion,greenwell-perfused
tissue with unaffected skin
as reference area) (upper
panel). Early and late stage
of indocyanine green mon-
itoring show the favourable
hyperaemicconditionsinthe
affected lesion from the very
beginning extending subse-
quently to the whole dorsum
of the hand (lower panel).
Thissevere extravasation in-
jury fully resolved with con-
servative management. Fig-
ure reproduced with permis-
sion from [16]
surgical intervention (Fig. 1) due to the development
of necrosis. Reversible tissue damage was associated
with hyperaemic conditions in the affected area even
in situations where the skin architecture was already
abolished as in the case of this ulceration under vi-
norelbine (Fig. 2, with permission from [16]). ICG an-
giography was therefore considered a good indicator
of local perfusion and a predictor of tissue damage.
This method, which can be performed on an out-
patient basis, was suitable to identify patients at risk
early after extravasation of vesicants.
One of the major unsolved problems is the man-
agement of central venous devices after extravasation
as drug may accumulate in the mediastinum, pleural
space or in the subcutaneous area of the chest or neck.
Although the implantation of a Port-a-Cath® was ini-
tially considered safe, extravasation rates up to 4.7%
have been reported. Therefore, the objective of the
third study was to investigate a possible procedure in
this difficult subset of patients [9]. Eight patients were
evaluated after port extravasation, mostly epirubicin
or platinum compounds. Immediate explantation of
the port was performed in combination with a “subcu-
taneous wash-out procedure” (SWOP) and compared
with delayed removal with débridement and flap cov-
erage. All three patients with immediate detection
of extravasation benefited from SWOP with accept-
able side effects (e. g. erythema). Interestingly, the
analysis of epirubicin concentrations using high pres-
sure liquid chromatography (HPLC) demonstrated the
active removal of compound by wound rinsing. In
contrast, late detection of extravasation led to major
complications (flap coverage in 4 out of 5 patients).
When detected early, SWOP was a beneficial option
for patients experiencing a severe extravasation event.
A high body mass index was a major risk factor for ex-
travasation.
Summary
Extravasation is a serious complication of chemother-
apy and can result in serious sequelae. A standard-
ised interdisciplinary approach to manage extravasa-
tions of cytotoxic agents should be implemented in
the hospital qualitymanagement system [4, 17]. A task
force quickly accumulates the necessary expertise to
handle even complex situations and raises the aware-
ness for this complication in the entire institution. As
a consequence, the incidence of surgical interventions
was acceptable because of the early consultation with
surgeons. For optimal management, it is important
to identify potential patient risk factors, to focus on
early detection and adequate management to miti-
gate possible consequences. As our knowledge is still
very limited, clinical and translational studies should
be encouraged as they help to optimise our interven-
tions in patients already in a difficult situation.
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